Liquid biopsy in lung cancer management
Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These ch...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593132/ https://www.ncbi.nlm.nih.gov/pubmed/36074665 http://dx.doi.org/10.47162/RJME.63.1.02 |
_version_ | 1784815090894110720 |
---|---|
author | Irofei Zamfir, Maria-Anca Buburuzan, Laura Hudiţă, Ariana Gălăţeanu, Bianca Ginghină, Octav Ion, Daniel Motaş, Natalia Ardeleanu, Carmen Maria Costache, Marieta |
author_facet | Irofei Zamfir, Maria-Anca Buburuzan, Laura Hudiţă, Ariana Gălăţeanu, Bianca Ginghină, Octav Ion, Daniel Motaş, Natalia Ardeleanu, Carmen Maria Costache, Marieta |
author_sort | Irofei Zamfir, Maria-Anca |
collection | PubMed |
description | Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These characteristics validate liquid biopsy analysis as a strong cancer biomarkers source with high potential for improving cancer patient’s evolution. Compared to classical biopsy, liquid biopsy is a minimal invasive procedure, and it allows the real-time monitoring of treatment response. Considering that lung cancer is the most common cause of cancer-associated death worldwide and that only 15–19% of the lung cancer patients survive five years after diagnosis, there is an important interest in improving its management. Like in other types of solid cancers, lung cancer could benefit from liquid biopsy through a simple peripheral blood sample as tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free nucleic acids (cfNA) [cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA)], exosomes and tumor-educated platelets (TEPs) may shed into circulation because of necrosis or in an active manner. More, the detection and analysis of these biomarkers could lead to a better understanding of oncological diseases like lung cancer. The better the tumor profile is established; the better management is possible. However, this approach has currently some limitations, such as low cfNA concentration or low count of CTCs that might be overcome by improving the actual methods and technologies. |
format | Online Article Text |
id | pubmed-9593132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest |
record_format | MEDLINE/PubMed |
spelling | pubmed-95931322022-11-14 Liquid biopsy in lung cancer management Irofei Zamfir, Maria-Anca Buburuzan, Laura Hudiţă, Ariana Gălăţeanu, Bianca Ginghină, Octav Ion, Daniel Motaş, Natalia Ardeleanu, Carmen Maria Costache, Marieta Rom J Morphol Embryol Review Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These characteristics validate liquid biopsy analysis as a strong cancer biomarkers source with high potential for improving cancer patient’s evolution. Compared to classical biopsy, liquid biopsy is a minimal invasive procedure, and it allows the real-time monitoring of treatment response. Considering that lung cancer is the most common cause of cancer-associated death worldwide and that only 15–19% of the lung cancer patients survive five years after diagnosis, there is an important interest in improving its management. Like in other types of solid cancers, lung cancer could benefit from liquid biopsy through a simple peripheral blood sample as tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free nucleic acids (cfNA) [cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA)], exosomes and tumor-educated platelets (TEPs) may shed into circulation because of necrosis or in an active manner. More, the detection and analysis of these biomarkers could lead to a better understanding of oncological diseases like lung cancer. The better the tumor profile is established; the better management is possible. However, this approach has currently some limitations, such as low cfNA concentration or low count of CTCs that might be overcome by improving the actual methods and technologies. Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest 2022 2022-08-23 /pmc/articles/PMC9593132/ /pubmed/36074665 http://dx.doi.org/10.47162/RJME.63.1.02 Text en Copyright © 2020, Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited. |
spellingShingle | Review Irofei Zamfir, Maria-Anca Buburuzan, Laura Hudiţă, Ariana Gălăţeanu, Bianca Ginghină, Octav Ion, Daniel Motaş, Natalia Ardeleanu, Carmen Maria Costache, Marieta Liquid biopsy in lung cancer management |
title | Liquid biopsy in lung cancer management |
title_full | Liquid biopsy in lung cancer management |
title_fullStr | Liquid biopsy in lung cancer management |
title_full_unstemmed | Liquid biopsy in lung cancer management |
title_short | Liquid biopsy in lung cancer management |
title_sort | liquid biopsy in lung cancer management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593132/ https://www.ncbi.nlm.nih.gov/pubmed/36074665 http://dx.doi.org/10.47162/RJME.63.1.02 |
work_keys_str_mv | AT irofeizamfirmariaanca liquidbiopsyinlungcancermanagement AT buburuzanlaura liquidbiopsyinlungcancermanagement AT huditaariana liquidbiopsyinlungcancermanagement AT galateanubianca liquidbiopsyinlungcancermanagement AT ginghinaoctav liquidbiopsyinlungcancermanagement AT iondaniel liquidbiopsyinlungcancermanagement AT motasnatalia liquidbiopsyinlungcancermanagement AT ardeleanucarmenmaria liquidbiopsyinlungcancermanagement AT costachemarieta liquidbiopsyinlungcancermanagement |